We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
-5.35%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.69B
AUM Growth
-$239M
Cap. Flow
+$33.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
47.52%
Holding
112
New
16
Increased
29
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
HD icon
Home Depot
HD
+$38M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$36.3M
3
ETNB
89bio
ETNB
+$36.1M
4
BAC icon
Bank of America
BAC
+$33.6M
5
CMG icon
Chipotle Mexican Grill
CMG
+$29.3M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$92M
2
KO icon
Coca-Cola
KO
+$48.2M
3
SBUX icon
Starbucks
SBUX
+$47M
4
CRH icon
CRH
CRH
+$41.5M
5
MCD icon
McDonald's
MCD
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 60.02%
2 Technology 10.47%
3 Consumer Discretionary 6.61%
4 Financials 5.33%
5 Communication Services 4.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTD icon
76
Mettler-Toledo International
MTD
$28.6B
$2.32M 0.09%
1,964
– –
MDT icon
77
Medtronic
MDT
$112B
$2.25M 0.08%
25,060
+7,600
+44% +$680K
SYK icon
78
Stryker
SYK
$130B
$2.18M 0.08%
5,860
+1,500
+34% +$571K
DXCM icon
79
DexCom
DXCM
$32B
$2.16M 0.08%
31,680
– –
TRVI icon
80
Trevi Therapeutics
TRVI
$2.64B
$2.14M 0.08%
+340,164
New +$1.62M
NTRA icon
81
Natera
NTRA
$46.4B
$1.43M 0.05%
10,100
– –
ORIC icon
82
Oric Pharmaceuticals
ORIC
$1.4B
$1.42M 0.05%
+255,000
New +$2.23M
IQV icon
83
IQVIA
IQV
$39.3B
$1.26M 0.05%
7,175
– –
CRH icon
84
CRH
CRH
$66.8B
$1.24M 0.05%
14,050
-422,344
-97% -$41.5M
MCK icon
85
McKesson
MCK
$101B
$1.23M 0.05%
1,830
– –
ELV icon
86
Elevance Health
ELV
$85.5B
$1.19M 0.04%
2,740
– –
AVTR icon
87
Avantor
AVTR
$9.19B
$1.16M 0.04%
71,850
– –
WAT icon
88
Waters Corp
WAT
$39.9B
$1.16M 0.04%
3,150
– –
SRPT icon
89
Sarepta Therapeutics
SRPT
$1.77B
$1.14M 0.04%
17,888
– –
HCA icon
90
HCA Healthcare
HCA
$89.5B
$1.1M 0.04%
3,190
– –
LKFT
91
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$932K 0.03%
37,111
– –
EW icon
92
Edwards Lifesciences
EW
$51.7B
$805K 0.03%
11,100
– –
A icon
93
Agilent Technologies
A
$41.2B
$584K 0.02%
4,990
– –
RMD icon
94
ResMed
RMD
$30.7B
$535K 0.02%
2,390
– –
VLTO icon
95
Veralto
VLTO
$24B
$534K 0.02%
5,475
– –
ZBH icon
96
Zimmer Biomet
ZBH
$18.4B
$369K 0.01%
3,260
– –
STE icon
97
Steris
STE
$23.1B
$347K 0.01%
1,530
– –
IONS icon
98
Ionis Pharmaceuticals
IONS
$9.4B
$326K 0.01%
10,800
– –
BAX icon
99
Baxter International
BAX
$14.2B
$273K 0.01%
7,970
– –
PACS icon
100
PACS Group
PACS
$7.67B
$225K 0.01%
20,000
– –
1 2 3
4
5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Suvretta Capital Management held 112 positions worth $2.69B, down 8.2% from $2.93B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Suvretta Capital Management's Q1 2025 filing shows 16 new, 29 increased, 14 reduced and 12 closed positions. Its largest new stake was Home Depot: 97,571 shares worth $35.8M. The largest sale was Intra-Cellular Therapies Inc., an estimated $92M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Suvretta Capital Management's largest Q1 2025 buy was Home Depot: 97,571 shares worth $35.8M.
  • Suvretta Capital Management added most to Ultragenyx Pharmaceutical in Q1 2025, an estimated $36.3M increase.
  • Suvretta Capital Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $92M.
  • Suvretta Capital Management fully exited Starbucks in Q1 2025, selling an estimated $47M.
  • Suvretta Capital Management's ten largest holdings make up 48% of its $2.69B portfolio in Q1 2025.
  • Suvretta Capital Management opened 16 new positions and closed 12 in Q1 2025.
  • Suvretta Capital Management's portfolio value fell 8.2% quarter-over-quarter to $2.69B.

Based on Suvretta Capital Management's 13F filing for Q1 2025, filed 15 May 2025.